Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01723228 · ClinicalTrials.gov registry record · Phase 4

Parallel-Group Study to Assess the Effect of Rasagiline on Cognition in Patients With Parkinson's Disease

A Phase 4 study of Parkinson's Disease, sponsored by Teva Branded Pharmaceutical Products R&D.

Completed
Registry status
Phase 4
Development phase
170
Enrollment target
20
Study locations

NCT01723228 is a Phase 4 study of Parkinson's Disease that has completed, run by Teva Branded Pharmaceutical Products R&D. The registered enrollment target is 170 participants, below the 641-participant average among 156 other Parkinson's Disease trials with a reported enrollment target (73% lower). The trial reports 20 study locations across 9 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01723228, a Phase 4 study of Parkinson's Disease, has completed, sponsored by Teva Branded Pharmaceutical Products R&D.

COMPLETED
Registry status
Phase 4
Development phase
170 participants
Enrollment target
20
Study locations

Study Summary

This is a 24-week, multicenter, randomized, double-blind, placebo-controlled, add-on, parallel-group study to evaluate the effect of rasagiline on cognitive function in adults with mild cognitive impairment (MCI) in Parkinson's disease (PD-MCI).

Conditions Studied

Parkinson's Disease

Interventions

  • DRUG Placebo
  • DRUG Rasagiline

Study Locations (20)

Florida

  • Teva Investigational Site 015 - Boca Raton
  • Teva Investigational Site 021 - Jacksonville
  • Teva Investigational Site 033 - Ormond Beach
  • Teva Investigational Site 020 - Port Charlotte
  • Teva Investigational Site 017 - St. Petersburg

California

  • Teva Investigational Site 004 - Irvine
  • Teva Investigational Site 016 - La Jolla
  • Teva Investigational Site 042 - Long Beach
  • Teva Investigational Site 041 - San Bernardino

Connecticut

  • Teva Investigational Site 035 - Danbury
  • Teva Investigational Site 034 - Manchester
  • Teva Investigational Site 037 - New London

Colorado

  • Teva Investigational Site 048 - Denver
  • Teva Investigational Site 038 - Englewood

Illinois

  • Teva Investigational Site 003 - Chicago
  • Teva Investigational Site 006 - Chicago

Alabama

  • Teva Investigational Site 036 - Birmingham

Arizona

  • Teva Investigational Site 047 - Sun City

District of Columbia

  • Teva Investigational Site 026 - Washington D.C.

Trial Details

FieldValue
Enrollment Target 170 participants
Start Date 2012-11
Est. Completion 2015-01
Phase Phase 4

Sponsor

Teva Branded Pharmaceutical Products R&D

167 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT01723228

The ClinicalTrials.gov registry entry for NCT01723228 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 170 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 641-participant average among 156 other Parkinson's Disease trials with a reported enrollment target (73% lower). The listed sponsor is Teva Branded Pharmaceutical Products R&D, which has 167 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Parkinson's Disease appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.

NCT01723228 reports 20 study locations spanning 9 distinct geographic areas - top geographies include Florida, California, Connecticut.

Frequently Asked Questions

What is clinical trial NCT01723228 about?

NCT01723228 is a clinical study titled "Parallel-Group Study to Assess the Effect of Rasagiline on Cognition in Patients With Parkinson's Disease". This is a 24-week, multicenter, randomized, double-blind, placebo-controlled, add-on, parallel-group study to evaluate the effect of rasagiline on cognitive function in adults with mild cognitive impairment (MCI) in Parkinson's disease (PD-MCI).

What is the current status of trial NCT01723228?

This trial is currently completed. It is a Phase 4 study. The enrollment target is 170 participants. The study started on 2012-11. Estimated completion is 2015-01.

What conditions does trial NCT01723228 study?

This clinical trial studies the following conditions: Parkinson's Disease.

What interventions are being tested in trial NCT01723228?

The interventions under investigation include: Placebo (DRUG), Rasagiline (DRUG).

Who is sponsoring clinical trial NCT01723228?

This trial is sponsored by Teva Branded Pharmaceutical Products R&D, which has 167 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT01723228 being conducted?

This trial has 20 study locations across Alabama, Arizona, California, Colorado, Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Parkinson's Disease

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Parkinson's Disease

All registered trials for this condition

Alabama

All trials with a study site in Alabama

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.